January 30, 2015 12:51 AM ET


Company Overview of MedImmune, LLC

Company Overview

MedImmune, LLC, a biologics research and development company, researches, develops, and explores medicines for unmet medical needs across therapeutic areas, including respiratory, inflammation, and autoimmunity; cardiovascular and metabolic disease; oncology; neuroscience; and infection and vaccines worldwide. It offers Synagis (palivizumab), a monoclonal antibody to prevent serious lower respiratory tract disease; FluMist Quadrivalent (Influenza Vaccine Live, Intranasal), a quadrivalent influenza vaccine; and Trivalent FluMist (T/LAIV), a live attenuated influenza vaccine. The company was incorporated in 1987 and is based in Gaithersburg, Maryland with locations in Mountain View, Santa Clar...

One MedImmune Way

Gaithersburg, MD 20878

United States

Founded in 1987

2,359 Employees





Key Executives for MedImmune, LLC

Vice President of Finance
Chief Operating Officer
Vice President
Senior Vice President of Biopharmaceutical Development
Age: 59
Executive Vice President
Compensation as of Fiscal Year 2014.

MedImmune, LLC Key Developments

MedImmune to Collaborate with US National Cancer Institute

MedImmune has entered into a research collaboration with the US National Cancer Institute (NCI) that focuses on cancer immunotherapy and tumour-targeted therapies for cancer. The initial four pre-clinical research projects will involve two projects that will assess combinations of immunotherapy compounds in new, mouse models, which represent human tumours better. Specifically, one project will evaluate combination activity of four agents - MEDI4736 (PD-L1), MEDI0680 (PD-1), tremelimumab (CTLA-4), and MEDI6469 (mOX40) - in genetically engineered mouse models. Meanwhile, other projects will assess cancer vaccine combinations with three compounds - MEDI4736, tremelimumab, and MEDI6469 (mOX40) - in pre-clinical models. The other two projects will assess antibodies that particularly attack tumour cells to evaluate molecular imaging of antibody drug conjugates and evaluate the therapeutic efficacy of cancer stem cells.

Tetragenetics Collaborates with MedImmune on Multi-Target Ion Channel Drug Discovery Program

Tetragenetics Inc. announced that it will collaborate with MedImmune on antibody drug discovery research. Specifically, Tetragenetics will use its proprietary ion channel production technology, SionX, to produce up to five ion channel antigens for MedImmune’s antibody drug discovery programs. MedImmune will be provided with target ion channel antigens on a non-exclusive basis. Tetragenetics will receive up-front license fees, research funding, and milestone payments associated with pre-clinical and clinical development as well as potential product sales.

MedImmune, LLC Presents at 7th annual Biotech Showcase Conference 2015, Jan-12-2015

MedImmune, LLC Presents at 7th annual Biotech Showcase Conference 2015, Jan-12-2015 . Venue: Parc 55 Wyndham San, Francisco - Union Square, San Francisco, CA 94102, United States.

Similar Private Companies By Industry

Company Name Region
Mintiva Holdings, L.L.C. United States
Calva Products Co., Inc. United States
NPIL Pharma, Inc. United States
Applied Analytical Industries Learning Center Inc United States
Sarasota Medical Products, Inc. United States

Recent Private Companies Transactions

November 4, 2014
Definiens AG
August 20, 2014
MedImmune, LLC, Global Rights to Ethyol®

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MedImmune, LLC, please visit www.medimmune.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.